ESTRO 2024 - Abstract Book

S5079

Physics - Radiomics, functional and biological imaging and outcome prediction

ESTRO 2024

Conclusion:

Clinically significant distinctions of PCa risk groups defined in terms of Ki67 and PSA are reflected in partially discriminative cut-off values derived from multiparametric MRI, PSMA-PET, and Acetate-PET. The ROC analysis suggests that PSMA-PET and mpMRI can contribute independent information to the classification. This information is valuable when guiding biopsies and defining regions for increased levels of radiation during radiotherapy.

Keywords: MRI, PET, histopathology

References:

1. Hammarsten, P. et al. Immunoreactivity for prostate specific antigen and Ki67 differentiates subgroups of prostate cancer related to outcome. Mod. Pathol. 32, 1310-1319 (2019). 2. Zellweger, T. et al. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small ‐ volume or low ‐ grade prostate cancer. Int. J. Cancer 124, 2116-2123 (2009). 3. Pinto, J. T. et al. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells.